Cabozantinib Clinical Trials

44 recruitingDrug
Phase 230Phase 113Phase 35Phase 41Early Phase 11

Showing 120 of 44 trials

Recruiting
Phase 2

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical Carcinoma+3 more
National Cancer Institute (NCI)48 enrolled55 locationsNCT06900595
Recruiting
Phase 1Phase 2

A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)

Metastatic Renal Cell CarcinomaTranslocation Renal Cell Carcinoma
Memorial Sloan Kettering Cancer Center43 enrolled8 locationsNCT06835972
Recruiting
Phase 2

Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial

Unresectable Digestive System Neuroendocrine Tumor G1Unresectable Digestive System Neuroendocrine Tumor G2Metastatic Digestive System Neuroendocrine Tumor G1+1 more
National Cancer Institute (NCI)100 enrolled33 locationsNCT05773274
Recruiting
Phase 2

A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

Renal Cell CarcinomaBrain Metastases
M.D. Anderson Cancer Center20 enrolled1 locationNCT05048212
Recruiting
Phase 2

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial

Metastatic Renal Cell CarcinomaStage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8+1 more
NRG Oncology240 enrolled318 locationsNCT05327686
Recruiting
Phase 1Phase 2

Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors,Gastroenteropancreatic
National Health Research Institutes, Taiwan49 enrolled11 locationsNCT05048901
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Solid Tumors With HRAS Alterations
Kura Oncology, Inc.300 enrolled37 locationsNCT06026410
Recruiting
Phase 2

Pan Tumor Rollover Study

Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.720 enrolled44 locationsNCT07011719
Recruiting
Phase 1Phase 2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb234 enrolled72 locationsNCT07293351
Recruiting
Phase 1

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

Solid TumorsClear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.362 enrolled29 locationsNCT05536141
Recruiting
Phase 3

Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)

Carcinoma, Renal CellVon Hippel-Lindau Disease
Merck Sharp & Dohme LLC450 enrolled4 locationsNCT07405164
Recruiting
Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled91 locationsNCT07227402
Recruiting
Phase 3

Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma
ECOG-ACRIN Cancer Research Group264 enrolled112 locationsNCT06475989
Recruiting
Phase 1

Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes

Metastatic Ewing Sarcoma
H. Lee Moffitt Cancer Center and Research Institute15 enrolled17 locationsNCT07194044
Recruiting
Phase 2

Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study

Metastatic OsteosarcomaRecurrent OsteosarcomaRefractory Osteosarcoma+2 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT05019703
Recruiting
Phase 2

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Meningioma
Baptist Health South Florida24 enrolled3 locationsNCT05425004
Recruiting
Phase 2

Cabozantinib Dose Skipping as an Alternative to Dose Reductions

Renal Cell Carcinoma (RCC)
dr. Tom van der Hulle34 enrolled1 locationNCT07077161
Recruiting
Phase 2

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer

Metastatic CancerCastration-resistant Prostate Cancer
Rana McKay, MD47 enrolled4 locationsNCT05502315
Recruiting
Phase 1Phase 2

Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies

Gastric CancerHepatocellular CarcinomaEsophageal Adenocarcinoma
Anwaar Saeed117 enrolled2 locationsNCT03539822